The Human Side of Biotech Partnering
By Anders Månsson, Senior Advisor at Ventures Accelerated
June 15, 2026
In biotech, “partnering” is one of those words that sounds deceptively wholesome. It evokes images of mutual support, shared goals, and perhaps even a celebratory handshake over a neatly signed term sheet. In practice, however, partnering, especially between a small, virtual biotech and a large pharmaceutical company, often resembles something closer to a high-stakes relationship: part courtship, part negotiation, and occasionally, part endurance sport.
At its best, partnering is a powerful accelerant. A small biotech, often built around a handful of scientists, a virtual operating model, and a bold hypothesis, gains access to resources it could never assemble on its own. Capital, clinical infrastructure, regulatory expertise, manufacturing scale, and global commercial reach suddenly come within striking distance. For a startup or scale-up navigating the treacherous path from discovery to market, this can mean the difference between a promising idea and an actual therapy reaching patients.
From the perspective of the larger company, the appeal is equally clear. External innovation has become a cornerstone of pharmaceutical and medtech strategy. Access to a particular niche technology can also provide a strategic edge for a CDMO. Rather than relying solely on internal R&D, large organizations increasingly look outward, tapping into the agility and creativity of smaller biotech companies. These partnerships can inject fresh science into mature pipelines, and they can diversify risk across multiple external bets. They can also add technological capability advantages.
On paper, it is a near-perfect symbiosis. In reality, as culture often differs significantly between large and small companies, it is more like a carefully negotiated marriage between two parties with very different habits, expectations, and tolerances for ambiguity.
The small biotech typically enters the relationship with urgency. Its timeline is measured in funding runways and inflection points. Every experiment matters, every delay has potential consequences, and every milestone can determine whether the company lives to raise another round. Decision-making is fast, often informal, and driven by a tight team, typically with a strong science and technology focus.
The large pharmaceutical, medtech, or CDMO partner often operates on a different clock. Its processes are designed for scale, compliance, and risk mitigation. Decisions move through layers of governance, committees, and internal alignment. What feels like prudent diligence on one side can feel like glacial inertia on the other.
This mismatch is not merely operational; it is often predominantly cultural. And like in human relationships, culture has a way of surfacing at the least convenient moments.
Consider the classic tension around control. A small biotech typically begins with a strong sense of ownership over its science. Yet partnering inherently involves compromise: shared decision-making, predefined development plans, and sometimes relinquishing autonomy over key aspects of the program.
For the larger partner, control is not about dominance so much as accountability. When committing significant capital and reputational risk, large companies seek structure and predictability. They want governance frameworks, clear milestones, and the ability to intervene if things go off track. From their perspective, this is simply responsible stewardship.
The result is a familiar dynamic: one party worries about losing its identity, while the other worries about losing its investment.
Communication, unsurprisingly, becomes critical - and frequently imperfect. In early-stage biotech, communication is often direct and unfiltered. In large organizations, it is more layered, sometimes cautious, occasionally opaque. Misalignment can creep in not because of bad intent, but because each side assumes the other operates with the same norms.
This is where the analogy to human partnerships becomes particularly clear. The most successful biotech alliances are not those that completely lack tension, but those that manage it constructively. They invest in clarity early: Who decides what? How are disagreements resolved? What does success look like, and over what timeframe?
Equally important is the recognition of asymmetry. Despite the language of “partnership,” these relationships are rarely equal in power. The large company typically controls more resources and, often, more optionality. The small biotech, meanwhile, may be heavily dependent on the success of a single program or deal. Pretending this asymmetry does not exist can lead to unrealistic expectations and, eventually, frustration.
Yet asymmetry does not have to mean imbalance in value. Small biotech companies bring something that large organizations cannot easily replicate, namely focus, speed, and a willingness to take scientific risks. When these qualities are preserved, rather than smoothed away by process, the partnership can create something that is genuinely greater than the sum of its parts.
There is also the question of timing, which in both corporate and human relationships can make or break the outcome. Partner too early, and a biotech may give away significant value before its science is fully validated. Partner too late, and it may struggle to finance the costly transition into clinical development. Striking the right balance, which is crucial, requires both strategic foresight and a realistic assessment of one’s own capabilities.
And then there is the subtle art of expectation management. In the early days of a deal, optimism tends to run high. Scientific potential is framed in its best light, timelines are ambitious, and both sides are eager to believe in a shared success story. Over time, as data accumulates and challenges emerge, expectations must adjust. The partnerships that endure are those that allow for recalibration without eroding trust.
It is worth noting that not all partnerships are meant to last forever. Some achieve their purpose and naturally conclude. Others evolve into deeper collaborations. A few unravel. In each case, the outcome is shaped less by the initial excitement and more by the day-to-day reality of working together.
For small, largely virtual biotech companies, the stakes are particularly high. With limited internal infrastructure, they often rely heavily on external partners not only for funding but also for execution. This makes the choice of partner - and the structure of the deal - one of the most consequential decisions they will make.
Due diligence, therefore, should run both ways. It is not enough to evaluate the financial terms; it is equally important to understand how the partner operates. How do they make decisions? How do they handle setbacks? What is their track record with other biotech collaborations? These questions, while less visible than headline deal values, often determine the lived experience of the partnership.
In the end, biotech partnering is neither a fairy tale nor a cautionary tale. It is a pragmatic tool - powerful, imperfect, and deeply human in its dynamics. Like any meaningful relationship, it requires alignment, communication, and a willingness to navigate differences.
And perhaps that is the most useful perspective to keep in mind. Behind the term sheets, governance committees, and milestone payments, are people trying to work together toward a shared goal. The science and technology may be complex, the stakes may be high, but the underlying principles are surprisingly familiar.
Choose your partner wisely, set expectations clearly, and remember that even in the world of molecules and markets, relationships still matter.
Do you need help in finding your ideal partner – Ventures Accelerated is here to guide you !